Cell cycle characteristics and EpsteinBarr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1513-1526

  Barros, Mrio Henrique M ^a   Scheliga, Adriana ^a   De Matteo, Elena ^b   Minnicelli, Carolina ^a   Soares, Fernando A ^c   Zalcberg, Ilana R ^a   Hassan, Rocio ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

childhood; EBV; Hodgkin lymphoma; nodular sclerosis; p53; proliferative index

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY KI 67; VINBLASTINE;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RISK; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; CHILD; CHILDHOOD CANCER; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EOSINOPHIL; EPSTEIN BARR VIRUS; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYMPTOM; TREATMENT OUTCOME;

EID: 77955455055     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.489243     Document Type: Article

References (40)

1. Thomson AB, Wallace WH. Treatment of paediatric Hodgkin's disease. A balance of risks. Eur J Cancer 2002;38: 468-477.
2. Diehl V, Klimm B, Re D. Hodgkin lymphoma: a curable disease: what comes next? Eur J Haematol Suppl 2005;(66): 6-13.
3. Morais A, Barros MH, Hassan R, Morais VL, Muniz MT. Number of involved anatomic areas as a risk predictor in pediatric Hodgkin's lymphoma: a retrospective study. J Pediatr (Rio J) 2009;85:236-242.
4. Hodgson DC, Hudson MM, Constine LS. Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol 2007;17:230-242.
5. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002;13:75-78.
6. van Spronsen DJ, Vrints LW, Hofstra G, Crommelin MA, Coebergh JW, Breed WP. Disappearance of prognostic significance of histopathological grading nodular sclerosing Hodgkin's disease for unselected patients, 1972-92. Br J Haematol 1997;96:322-327.
7. Bai M, Papoudou-Bai A, Kitsoulis P, et al. Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas. In Vivo 2005;19:439-453.
8. Montalbán C, Garciá JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22:1664-1673.
9. Ambinder RF. Epstein-Barr virus and Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007:204-209.
10. Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates upregulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008;173:195-204.
11. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765-3775.
12. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-3375.
13. Stein H, Delsol G, Pileri S, Weiss LM, Poppema S, Jaffe ES. Hodgkin lymphoma. In: Swerdlow SH, Campos E, Harris NL, et al. editors. World Health Organization classification of tumors. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp 326-329.
14. MacLennan KA, Bennett MH, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease: a study of 1659 patients. Cancer 1989;64:1686-1693.
15. von Wasielewski S, Franklin J, Fischer R, et al. Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages. Blood 2003;101:4063- 4069.
16. Zhou XG, Sandvej K, Li PJ, et al. Epstein-Barr virus (EBV) in Chinese pediatric Hodgkin disease: Hodgkin disease in young children is an EBV-related lymphoma. Cancer 2001;92:1621- 1631.
17. Smolewski P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res 2000;6:1150-1160.
18. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL- 2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100: 3935-3941.
19. Sup SJ, Alemañy CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005;23:3773-3779.
20. Chilosi M, Doglioni C, Magalini A, et al. p21/WAF1 cyclinkinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 1996;88:4012-4020.
21. Chabay P, Pesce P, De Matteo E, Lombardi MG, Rey G, Preciado MV. No influence of bcl-2, p53 and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas. J Pediatr Hematol Oncol 2006;28:552-558.
22. Hassan R, White LR, Stefanoff CG, et al. Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol 2006;1:17-22.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
24. Mantel N. Evaluation of survival data and two new rank-order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
25. Schwartz CL. Special issues in pediatric Hodgkin's disease. Eur J Haematol 2005;75:55-62.
26. Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1602-1608.
27. Schellong G, Pötter R, Brämswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German- Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
28. Viani GA, Castilho MS, Novaes PE, et al. Chemotherapy followed by low dose radiotherapy in childhood Hodgkin's disease: retrospective analysis of results and prognostic factors. Radiat Oncol 2006;1:38.
29. Claviez A, Tiemann M, Peters J, Kreipe H, Schneppenheim R, Parwaresch R. The impact of EBV, proliferation rate, and Bcl-2 expression in Hodgkin's disease in childhood. Ann Hematol 1994; 68:61-66.
30. Oguz A, Karadeniz C, Okur FV, et al. Prognostic factor and treatment outcome in childhood Hodgkin disease. Pediatr Blood Cancer 2005;45:670-675.
31. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combinedmodality therapy. J Clin Oncol 2003;10:2026-2033.
32. Chabay PA, Barros MH, Hassan R, et al. Pediatric Hodgkin lymphoma in 2 South American series: a distinctive epidemiologic pattern and lack of association of Epstein-Barr virus with clinical outcome. J Pediatr Hematol Oncol 2008;30:285-291.
33. Wang J, Taylor CR. Apoptosis and cell cycle-related genes and proteins in classical Hodgkin lymphoma: application of tissue microarray technique. Appl Immunohistochem Mol Morphol 2003;11:206-213.
34. Tiemann M, Claviez A, Lüders H, et al. Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase. Mod Pathol 2005;18:1440- 1447.
35. Dinand V, Malik A, Unni R, Arya LS, Pandey RM, Dawar R. Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer 2008;50:280-283.
36. Desmouliére A, Darby IA, Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest 2003;83:1689-1707.
37. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. Hum Pathol 2009;40:1365-1376.
38. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol 2001;67:279-288.
39. Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996;88:3299-3305.
40. Zander T, Wiedenmann S, Wolf J. Prognostic factors in Hodgkin's lymphoma. Ann Oncol 2002;13:67-74.